Fortress Biotech, Inc.: updates and filings

FBIONASDAQHealthcare · Pharmaceutical Preparations

Price

$1.89

November 18, 2026Market cap $59M

What Ploutos Investor adds for Fortress Biotech

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 13 fiscal years, from 2013
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The reported profit is far larger than a business usually earns on its market value, which usually means one-off or accounting gains. We leave out the P/E and the earnings yield.
  • The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
  • A figure that did not match the numbers it is built from has been left out.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 86 daysAround Feb 12, 2027 · for Q4 2026

last Nov 13, 2026next Feb 12, 2027

An estimate from when it has reported before, which has been regular. The company announces the date itself.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Mar 31, 2026 latest annualNov 13, 2026 latest quarterly
  • Nov 13, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Nov 13, 2026Results of operations
    Form8-K
  • Oct 29, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Oct 1, 2026Other material events
    Form8-K
  • Sep 1, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Aug 13, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 13, 2026Results of operations
    Form8-K
  • Jun 23, 2026Shareholder vote
    Form8-K
  • May 15, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • May 14, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q
  • May 14, 2026Results of operations
    Form8-K
  • Apr 28, 2026Additional annual meeting material
    FormDEFA14A
  • Apr 28, 2026Annual meeting proxy statement
    FormDEF 14A
  • Mar 31, 2026Annual reportfor the period to Dec 31, 2025
    Form10-K
  • Mar 31, 2026Results of operations
    Form8-K
  • Mar 30, 2026Other material events
    Form8-K
  • Mar 20, 2026Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • Feb 23, 2026Material agreement entered, new material financial obligation, other material events
    Form8-K
  • Jan 13, 2026Other material events
    Form8-K
  • Jan 6, 2026Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • Jan 5, 2026Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • Dec 17, 2025Filing
    FormEFFECT
  • Dec 16, 2025Correspondence with the SEC
    FormCORRESP
  • Dec 16, 2025FORM S-1
    FormS-1
  • Dec 15, 2025Material agreement entered, new material financial obligation, unregistered sale of shares
    Form8-K

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Mar 5, 2008. Of its note and share prospectuses (424B, FWP), the newest 40 of 45.

The full analysis

What do Fortress Biotech's filings show?

The filings are where every one of Fortress Biotech's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.